Initial Tx for 65 yo, int-2, sympt MF, baseline anemia? High-risk MF, anemia develops on Rux: Adjust dose?Initial Tx for 65 yo, int-2, sympt MF, baseline anemia? High-risk MF, anemia develops on Rux: Adjust dose?Which treatment would you most likely initiate for a 65-year-old patient with intermediate-2 myelofibrosis, splenomegaly and significant disease-related symptomatology who has already received EPO and danazol:
Additional CommentaryAdditional Commentary:What is the role of iron chelation for patients with MF who have frequent transfusion requirements? Additional CommentaryAdditional Commentary:How common is the occurrence of hydroxyurea-related leg ulcers? Additional CommentaryAdditional Commentary:Is there cross-resistance between ruxolitinib and other JAK2 inhibitors? COCMF13/2TARGET AUDIENCE Patterns of Care Data Regarding Ruxolitinib Use in Patients without JAK2 MutationsPatterns of Care Data Regarding Ruxolitinib Use in Patients without JAK2 Mutations Additional CommentaryAllotransplant in patients with MF?In what situations, if any, do you recommend allotransplant to patients with MF? Additional CommentarySplenectomy in patients with MF?Presently, how often do you recommend splenectomy to patients with MF? Additional CommentaryOther diseases most commonly confused with MF?Based on your clinical experience, which of the following disease states is most often confused with a diagnosis of myelofibrosis (MF)? COCMF13/1TARGET AUDIENCE  |